Investor Alert
Vascepa® (icosapent ethyl) cardiovascular outcomes study, REDUCE-IT™, results are available.
See press release here

DISCOVER

Vascepa®

EXPERIENCED

in lipid science

INVESTOR

relations

Vascepa®

LIPID SCIENCE

investor relations

welcome


therapeutics to improve cardiovascular health

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription. For more information about Vascepa visit www.vascepa.com.

Vascepa


The History of Vascepa

Development of Vascepa leveraged Amarin’s extensive experience in lipid sciences and the potential therapeutic benefits of polyunsaturated fatty acids. Such development challenged previously established norms to create a potent, yet safe, targeted single ingredient product in contrast to prior generation omega-3 mixtures and other prescription drugs. The use of Vascepa is now supported by over 40 granted patents and by FDA designation in 2015 of Vascepa’s active ingredient as a New Chemical Entity. This means that no prior FDA-approved drug had the active ingredient contained in Vascepa. Also, no prior drug with icosapent ethyl was ever characterized for FDA review and approved by the FDA to treat or prevent a medical condition.

MORE

recent news


29 Mar 2019

Vascepa® Granted Priority Review Status from Health Canada New Drug Submission (NDS) for Vascepa in Canada Anticipated to Be Filed in April 2019 by HLS Therapeutics, Under Agreement with Amarin MORE

28 Mar 2019

Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT™ Cardiovascular Outcomes Study MORE

Stock Information

Symbol:
AMRN (NASDAQ)
Quote:
$18.06
Change:
+0.40
Date:
4:00 PM EDT on Apr 18, 2019
(latest end of day stock price)
Investor
Relations
Executive
Team
Career
Opportunities
FAQs
Contact
Amarin

Amarin
Corporation

therapeutics to improve
cardiovascular health.

Join Our Mailing List

You may automatically receive Amarin Corporation plc financial information by email.


Click To Subscribe